Search Medical Condition
Please enter condition
Please choose location

Plainfield, New Jersey Clinical Trials

A listing of Plainfield, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (195) clinical trials

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care. Data will be collected on the safety and effectiveness of treatment with Gliadel Wafer perioperatively and ongoing during regular office visits up to 3-years. Patients enrolled in this ...

Phase N/A

4.17 miles

Learn More »

Study to Assess the Efficacy Safety and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression Agitation and Irritability in Patients With Traumatic Brain Injury

Eligible participants for this study must have a diagnosis of neurobehavioral disinhibition including aggression, agitation, and irritability that persists after brain injury. This is a multicenter, randomized, placebo-controlled study, consisting of up to 12 weeks of treatment.

Phase

4.17 miles

Learn More »

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, is a prospective, randomized, double-blind, multicenter trial with the primary null hypothesis that, in patients with TIA or minor ischemic stroke treated with aspirin 50-325 mg/day, there is no difference in the event-free survival at 90 days in those ...

Phase

4.17 miles

Learn More »

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular Marginal Zone or Mantle Cell Lymphoma.

MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) who received ≥1 prior therapy and had stage I-IV, measurable disease. ~500 patients are planned for enrollment in 12 cycles of R2 ...

Phase

4.25 miles

Learn More »

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK) **Please note that the study is no longer enrolling patients for Groups A, B, C, and E.

Phase

4.25 miles

Learn More »